Trials / Unknown
UnknownNCT05719701
Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma
A Multi-center, Non-randomized, and Open-label Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, non-randomized and open-label phase I/IIa clinical study to evaluate the safety, tolerability, and efficacy of ICP-490 in patients with relapsed and/or refractory multiple myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ICP-490 | Several dose groups of ICP-490 are planned for the dose exploration. |
| DRUG | Dexamethasone | Oral Dexamethasone is administered on Days 1, 8, 15, and 22 of each 28-day cycle. |
Timeline
- Start date
- 2023-03-29
- Primary completion
- 2025-07-30
- Completion
- 2025-12-30
- First posted
- 2023-02-09
- Last updated
- 2024-04-09
Locations
6 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05719701. Inclusion in this directory is not an endorsement.